Ogalvibart

Cat. No.: HY-145644

CAS No.: 2599039-60-6

Target: SARS-CoV

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1].
IC_{50} & Target	SARS-CoV-2[1].
In Vivo	Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rhesus macaques (3-11 years old)[1].
Dosage:	10 mg/kg (in combination with 10 mg/kg C144LS)
Administration:	75 days before infection
Result:	Protected a subset of animals whose infectious challenge was 75 days post administration from disease.

REFERENCES

[1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA